Presentation of Ophthalmology Clinical Trial Data at ARVO
Filed with ASX · · 70 pages · English
Summary by 6ix AI
PYC Therapeutics Limited has announced the presentation of clinical trial data at the ARVO conference, focusing on two investigational drug candidates for childhood blinding eye diseases. This presentation aims to showcase the potential of these therapies as first approved treatment options for these conditions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
PYC Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from PYC Therapeutics
- ADOA Program - SRC Approve Progression to Multi-Dose Study
- Completion of Retail Entitlement Offer
- PKD Clinical Trial - Approval to Escalate Dosing
- Half Yearly Report and Accounts
- Retail Offer Booklet
Later from PYC Therapeutics
- PKD - Initiation of Multiple Dose Clinical Trial
- ADOA Program Update
- PKD - Safety Committee Approves Dose Escalation
- Quarterly Activities/Appendix 4C Cash Flow Report
- Notification regarding unquoted securities - PYC
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics